**Core Concept**
Abatacept is a medication used in the treatment of rheumatoid arthritis, which targets the immune system's T-cells to prevent them from attacking the body's joints. It works by inhibiting the interaction between T-cells and antigen-presenting cells, thereby reducing inflammation and joint damage.

**Why the Correct Answer is Right**
Abatacept is a selective co-stimulation modulator, which means it specifically binds to CD80 and CD86 on antigen-presenting cells, preventing their interaction with CD28 on T-cells. This action reduces the activation of T-cells, which are responsible for the inflammatory response in rheumatoid arthritis. By inhibiting this interaction, abatacept decreases the production of pro-inflammatory cytokines and slows disease progression.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because abatacept is not a biologic DMARD (disease-modifying antirheumatic drug) that targets tumor necrosis factor-alpha (TNF-alpha) like infliximab or etanercept.
**Option B:** Incorrect because abatacept is not a traditional DMARD like methotrexate, which works by suppressing the immune system through various mechanisms.
**Option C:** Incorrect because abatacept is not a JAK (Janus kinase) inhibitor like tofacitinib, which targets the signaling pathway of cytokines like IL-2, IL-4, and IL-6.

**Clinical Pearl / High-Yield Fact**
Abatacept is often used in combination with other DMARDs to achieve better clinical outcomes in patients with rheumatoid arthritis. Its mechanism of action makes it a valuable option for patients who have not responded to other treatments or have a high risk of adverse effects from traditional DMARDs.

**Correct Answer: C. Abatacept is a selective co-stimulation modulator that inhibits the interaction between T-cells and antigen-presenting cells, thereby reducing inflammation and joint damage in rheumatoid arthritis.**